Editor of Patient Care Online.
FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose
Your daily dose of the clinical news you may have missed.
Vaccination Information and Educational Resources from the National Foundation for Infectious Diseases
Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.
New Data Suggest Revised Colorectal Cancer Screening Guidelines Strain Community Health Centers
The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.
NFID Medical Director Highlights ACIP Rationale for Lowering Age for Pneumococcal Vaccination
Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.
Mailed FIT Outreach Increases CRC Screening Rates: Daily Dose
Higher Daily Step Count Linked to Lower Risk for Depression Among Adults
Daily step counts of 5000 or more corresponded with fewer depressive symptoms, according to a recent systematic review and meta-analysis.
Addressing the Gap: Advocacy Groups Call for Inclusion of Patients with Obesity in Clinical Trials
President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.
FDA Approves First Drug for Obstructive Sleep Apnea with Obesity: Daily Dose
Clinician Education on Obesity Has Not Caught Up to Disease State, Says OMA President
Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.
FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes
The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.
New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose
Smartphone App Shows Promise for Managing Hypertension in Observational Study
People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.
Atogepant Improves QoL in Chronic, Episodic Migraine: Daily Dose
Targeted Intervention Boosts Colorectal Cancer Screening Rates among Underserved US Adults
A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data
Fremanezumab for Prevention of Episodic Migraine in Children: Daily Dose
Brexpiprazole and Sertraline Combination Therapy Shows Efficacy in Treating PTSD
New findings highlight the potential of this combination therapy as a new option for people with PTSD who have not responded to standard treatments.
US Adults Lagging in Flu, COVID-19, and RSV Vaccination: Daily Dose
10 Essential Vaccine Updates for Primary Care
From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.
Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose
FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis
Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.
January Issue of Patient Care Online Digital Edition is Now Live
Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.
Tirzepatide Superior to Semaglutide in Weight Loss Trial: Daily Dose
Expert Perspectives 2024: The Dynamic Future of Obesity Medicine, with Donna Ryan, MD
The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.
FDA Review Sought for Lumateperone as Adjunctive Therapy for Major Depressive Disorder
Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone for the treatment of MDD in adults as as adjunctive therapy to antidepressants.
Role of Sleep in Dementia and Associated Comorbidities: Daily Dose
Emerging Obesity Research to Watch For in 2025
Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.
Antiobesity Drugs May Help Curb Alcohol Consumption: Daily Dose
The Evolving Perception and Utilization of Antiobesity Drugs: Expert Discussion
Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.
Most US Adults Want Primary Care Physicians to Address Mental Health: Daily Dose
